Set to expand the wealth of knowledge and further pioneer the care and treatment of men with prostate cancer, Dr Stricker is this year engaging in a new clinical trial. Having commenced in early 2012 the trial focuses on low risk prostate cancers and the role of Magnetic Resonance Imaging (MRI).
Open to all men with low risk prostate cancers who are engaged in active surveillance, the result will add more scientific information to assist patients in choosing the most appropriate treatment. In particular, the trial will focus on the way in which active surveillance and MRI are used to assess the size and progression of the cancer as well as to minimise the number of biopsies.
It is anticipated that the results of the clinical trial will be available in two years.